AbbVie Inc. Cash & Equivalents 2010-2026 | ABBV
Beta
What is cash & equivalents?
Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.
What is AbbVie Inc.'s current cash & equivalents?
AbbVie Inc. (ABBV) annual cash & equivalents for 2025 was $5.23B, a 5.34% decline from 2024. AbbVie Inc. cash & equivalents for the quarter ending March 31, 2026 was $9.39B.
What was AbbVie Inc.'s cash & equivalents in 2024?
AbbVie Inc. annual cash & equivalents for 2024 was $5.52B, a 56.89% decline from 2023.
What was AbbVie Inc.'s cash & equivalents in 2023?
AbbVie Inc. annual cash & equivalents for 2023 was $12.81B, a 39.27% increase from 2022.
What is AbbVie Inc.'s 5-year cash & equivalents CAGR?
AbbVie Inc. cash & equivalents grew at a compound annual growth rate (CAGR) of 9.15% from FY2020 to FY2025, going from $8.45B to $5.23B over 5 years.
Cash & Equivalents History
Year-over-year comparison from 10-K annual reports
Key Statistics
Trend Direction
Declining
CAGR-9.2%
FY2020
$8.45B
→
FY2025
$5.23B
10111213141516171819202122232425
5 years selected
Cash & Equivalents History
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $5.23B | -5.3% | 10-K |
| FY2024 | $5.52B | -56.9% | 10-K |
| FY2023 | $12.81B | +39.3% | 10-K |
| FY2022 | $9.20B | -5.6% | 10-K |
| FY2021 | $9.75B | +15.4% | 10-K |
| FY2020 | $8.45B | -78.8% | 10-K |
| FY2019 | $39.92B | +447.7% | 10-K |
| FY2018 | $7.29B | -21.6% | 10-K |
| FY2017 | $9.30B | +82.4% | 10-K |
| FY2016 | $5.10B | -39.3% | 10-K |
| FY2015 | $8.40B | +0.6% | 10-K |
| FY2014 | $8.35B | -13.0% | 10-K |
| FY2013 | $9.60B | +62.6% | 10-K |
| FY2012 | $5.90B | +21755.6% | 10-K |
| FY2011 | $27.0M | +170.0% | 10-K |
| FY2010 | $10.0M | - | 10-K |
Company: AbbVie Inc.Ticker: ABBVSector: HealthcareIndustry: Pharmaceutical PreparationsView company profile →